Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Goedele de Smedt"'
Autor:
Steven Nijs, Thomas N. Kakuda, Veerle Vyncke, Monika Peeters, Goedele De Smedt, Richard M. W. Hoetelmans, Lorant Leopold, Ruud Leemans, Cindy Berckmans, Rodica Van Solingen-Ristea
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 51:725-736
Objectives Three studies were conducted to assess the pharmacokinetics, methods of administration and ease of swallowability of etravirine tablets. Methods Two randomized studies in healthy adults investigated the single-dose pharmacokinetics of etra
Autor:
Maxwell D. Cummings, Goedele De Smedt, Leen Vijgen, Bart Fevery, Jan Martin Berke, Christophe Moreno, Oliver Lenz, Gaston Picchio, Monika Peeters
Publikováno v:
Journal of Hepatology. 58:445-451
Background & Aims TMC435 is a potent, once-daily, investigational hepatitis C virus (HCV) NS3/4A protease inhibitor in phase III clinical development. In the phase II trial TMC435-C202 (NCT00812331), TMC435 displayed potent activity in genotype 4, 5
Autor:
James Witek, Goedele De Smedt, Veerle Vyncke, Richard M. W. Hoetelmans, Thomas N. Kakuda, Kurt Spittaels, Monika Schöller-Gyüre, Sophie H. Akuma
Publikováno v:
The Journal of Clinical Pharmacology. 53:202-210
Background A previous study investigating coadministration of etravirine, a nonnucleoside reverse transcriptase inhibitor, and lopinavir/ritonavir soft-gel formulation resulted in nonclinically relevant changes in etravirine and lopinavir exposure. T
Autor:
Thomas N. Kakuda, Veerle Vyncke, Fatima Aharchi, Rodica Van Solingen-Ristea, Richard M. W. Hoetelmans, Goedele De Smedt, Steven Nijs, James Witek
Publikováno v:
The Journal of Clinical Pharmacology. 53:41-50
The nonnucleoside reverse transcriptase inhibitor etravirine, approved for use in treatment-experienced, HIV-1-infected patients, is a substrate and inducer of cytochrome P450 (CYP) 3A4 and a substrate and inhibitor of CYP2C9/CYP2C19. Pharmacokinetic
Autor:
Steven Nijs, Johan Vingerhoets, Goedele De Smedt, Sandra De Meyer, Inge Dierynck, Hilde Azijn, Laurence T. Rimsky, Gaston Picchio, Marie-Pierre de Béthune, Lotke Tambuyzer
Publikováno v:
AIDS Research and Human Retroviruses. 26:621-624
Etravirine (ETR) has previously shown potent in vitro activity against different primary HIV-1 isolates and demonstrated durable efficacy in treatment-experienced, HIV-1-infected patients in the Phase III DUET studies. The antiviral activity and effi
Autor:
Annemie Hoogstoel, Goedele De Smedt, Monika Peeters, Steven Nijs, Johan Vingerhoets, Marie-Pierre de Béthune, Hilde Azijn, Brian Woodfall, Gaston Picchio, Lotke Tambuyzer
Publikováno v:
AIDS. 24:503-514
Objective: To refine the genotypic and phenotypic correlates of response to the nonnucleoside reverse transcriptase inhibitor etravirine. Design: Initial analyses identified 13 etravirine resistance-associated mutations (RAMs) and clinical cutoffs (C
Autor:
Thomas N. Kakuda, Goedele De Smedt, Richard M. W. Hoetelmans, Monika Schöller-Gyüre, Araz Raoof
Publikováno v:
Clinical Pharmacokinetics. 48:561-574
Etravirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for the treatment of HIV-1 infection. It has a high genetic barrier to the emergence of viral resistance, and maintains its antiviral activity in the pre
Autor:
Thomas N Kakuda, Monika Schöller-Gyμre, Cassy Workman, Keikawus Arasteh, Anton L Pozniak, Goedele De Smedt, Greet Beets, Monika Peeters, Kati Vandermeulen, Brian J Woodfall, Richard MW Hoetelmans
Publikováno v:
Antiviral Therapy. 13:655-661
Background An open-label, randomized, crossover study to evaluate the pharmacokinetics of two different formulations of etravirine after single and multiple dosing. Methods Treatment-experienced HIV-1-infected patients with viral load Results After s
Autor:
Monika Schöller-Gyüre, Brian Woodfall, Katrien Janssen, Ruth Lachaert, Goedele De Smedt, Monika Peeters, Thomas N. Kakuda, Richard M. W. Hoetelmans
Publikováno v:
Annals of Pharmacotherapy. 42:757-765
Background: Etravirine (TMC125), a next-generation nonnucleoside reverse transcriptase inhibitor, has shown antiviral efficacy in 2 large Phase 3 trials. In vitro and in vivo studies have shown that etravirine is not associated with proarrhythmic pot
Autor:
Goedele De Smedt, Wim van den Brink, Hilde Vanaken, Richard M. W. Hoetelmans, Thomas N. Kakuda, Monika Schöller-Gyüre, Monika Peeters, Brian Woodfall, Kati Vandermeulen, Tanja Stevens
Publikováno v:
Journal of clinical pharmacology, 48(3), 322-329. Wiley-Blackwell
TMC125 is a nonnucleoside reverse transcriptase inhibitor (NNRTI) with potent in vitro activity against wild-type and NNRTI-resistant HIV-1. TMC125 is an inducer of CYP3A and an inhibitor of CYP2C. This trial evaluated the effect of TMC125 on the pha